Suppr超能文献

微小肿瘤大小与阳性淋巴结胰腺癌患者总生存时间降低相关。

Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer.

机构信息

Harvard Radiation Oncology Program, Boston, MA, USA.

Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.

出版信息

Ann Surg Oncol. 2018 Dec;25(13):4027-4034. doi: 10.1245/s10434-018-6832-8. Epub 2018 Oct 8.

Abstract

BACKGROUND

In pancreatic adenocarcinoma (PDAC), increasing tumor size usually correlates with a worse prognosis. However, patients with a very small primary tumor who experience lymph node involvement may have a different disease biology. This study sought to determine the interaction between tumor size and lymph node involvement in terms of overall survival (OS).

METHODS

The study identified 17,073 patients with a diagnosis of M0 resected PDAC between 1983 and 2013 using the Surveillance, Epidemiology, and End Results database. The patients were stratified by lymph node involvement (N0 vs N+) and T stage (T1a-T1b vs T1c vs T2 vs T3 vs T4). The Kaplan-Meier method was used to estimate OS, and Cox regression analysis was used to compare survival between subgroups after adjustment for patient-specific factors.

RESULTS

Lymph node involvement and T stage significantly interacted (p < 0.001). Among the patients with node-negative disease, 5-year OS decreased monotonically with increasing T stage (59.1%, 30.6%, 22.9%, 16.6%, and 8.0%, respectively; p < 0.001). In contrast, among the patients with node-positive disease, those with T1a-T1b tumors (< 10 mm) had worse 5-year OS than those with T1c tumors (7.4% vs 17.6%; adjusted hazard ratio, 0.70; 95% confidence interval, 0.50-0.97; p = 0.034) and similar survival compared with those who had T2, T3, or T4 tumors (9.7%, 8.2%, and 4.8%, respectively; p > 0.2 in all cases).

CONCLUSIONS

Among patients with lymph node-positive PDAC, very small primary tumors are associated with decreased OS. This finding raises the possibility that small tumors capable of lymph node metastasis might represent more biologically aggressive cancers.

摘要

背景

在胰腺导管腺癌(PDAC)中,肿瘤体积增大通常与预后较差相关。然而,经历淋巴结受累的体积非常小的原发肿瘤患者可能具有不同的疾病生物学特性。本研究旨在确定肿瘤大小和淋巴结受累在总生存(OS)方面的相互作用。

方法

本研究使用监测、流行病学和最终结果(SEER)数据库,确定了 1983 年至 2013 年间诊断为 M0 可切除 PDAC 的 17073 例患者。根据淋巴结受累(N0 与 N+)和 T 分期(T1a-T1b 与 T1c 与 T2 与 T3 与 T4)对患者进行分层。Kaplan-Meier 法用于估计 OS,Cox 回归分析用于调整患者特定因素后比较亚组之间的生存。

结果

淋巴结受累和 T 分期显著相互作用(p<0.001)。在淋巴结阴性疾病患者中,随着 T 分期的增加,5 年 OS 呈单调下降趋势(分别为 59.1%、30.6%、22.9%、16.6%和 8.0%;p<0.001)。相比之下,在淋巴结阳性疾病患者中,T1a-T1b 肿瘤(<10mm)患者的 5 年 OS 比 T1c 肿瘤患者差(7.4%比 17.6%;调整后的风险比,0.70;95%置信区间,0.50-0.97;p=0.034),与 T2、T3 或 T4 肿瘤患者的生存相似(分别为 9.7%、8.2%和 4.8%;在所有情况下 p>0.2)。

结论

在淋巴结阳性 PDAC 患者中,非常小的原发肿瘤与 OS 降低相关。这一发现提出了这样一种可能性,即能够发生淋巴结转移的小肿瘤可能代表更具侵袭性的癌症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验